PHASERX INC CM ST (OTCMKTS:PZRXQ) Sellers Declined Their Shorts By 93.53%

PHASERX INC CM ST (OTCMKTS:PZRXQ) registered a decrease of 93.53% in short interest. FINRA published short interest of PZRXQ’s total 1,500 shares. Previously was reported down change of 93.53% from 23,200 shares.

$0.0033 was the last price.It’s since December 6, 2017 and is 0.00% down. PZRXQ underperformed the S&P500 by 15.62%.

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy.The firm is valued at $38,577. The firm develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell.Last it reported negative earnings. The Company’s therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.